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Abstract
Background:  The antihyperglycemic drug metformin may have beneficial effects on the
prevention and treatment of cancer. Metformin is known to activate AMP-activated protein kinase
(AMPK). It has also been shown to inhibit cyclin D1 expression and proliferation of some cultured
cancer cells. However, the mechanisms of action by which metformin mediates cell cycle arrest are
not completely understood.
Results: In this study, metformin was found to inhibit proliferation of most cultured breast cancer
cell lines. This was independent of estrogen receptor, HER2, or p53 status. Inhibition of cell
proliferation was associated with arrest within G0/G1 phase of the cell cycle. As in previous studies,
metformin treatment led to activation of (AMPK) and downregulation of cyclin D1. However, these
events were not sufficient for cell cycle arrest because they were also observed in the MDA-MB-
231 cell line, which is not sensitive to growth arrest by metformin. In sensitive breast cancer lines,
the reduction in cyclin D1 led to release of sequestered CDK inhibitors, p27Kip1 and p21Cip1, and
association of these inhibitors with cyclin E/CDK2 complexes. The metformin-resistant cell line
MDA-MB-231 expresses significantly lower levels of p27Kip1 and p21Cip1 than the metformin-
sensitive cell line, MCF7. When p27Kip1 or p21Cip1 were overexpressed in MDA-MB-231, the cells
became sensitive to cell cycle arrest in response to metformin.
Conclusion: Cell cycle arrest in response to metformin requires CDK inhibitors in addition to
AMPK activation and cyclin D1 downregulation. This is of interest because many cancers are
associated with loss or downregulation of CDK inhibitors and the results may be relevant to the
development of anti-tumor reagents that target the AMPK pathway.
Background
Metformin hydrochloride (N, N-dimethylimidodicarbon-
imidic diamide hydrochloride) is a commonly prescribed
oral antihyperglycemic drug used in the management of
Type 2 diabetes. Recent evidence indicates that metformin
has significant effects on tumorigenesis and cancer cell
growth. It was reported that patients with Type 2 diabetes
who are prescribed metformin have a lower risk of cancer
compared to patients that do not take metformin [1,2]. In
a mouse xenograft model, metformin suppressed tumor
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growth of p53 negative HCT116 colon cancer cells, but
not of p53 wild-type cells [3]. Metformin treatment
decreases the incidence and size of mammary adenocarci-
nomas in Her2/Neu mice [4] and prevents carcinogen-
induced pancreatic cancer in hamsters [5]. In culture, met-
formin has been shown to inhibit growth of cells derived
from breast cancer, colon cancer, prostate cancer, and gli-
omas [3,6-9]. However, the mechanisms of action by
which metformin mediates these beneficial effects on can-
cer cell growth are not well understood.
One intracellular target of metformin is the activation of
adenosine 5'-monophosphate-activated kinase (AMPK)
[10]. AMPK consists of three subunits, α,β and γ, and each
subunit has at least two isoforms [11]. Activation of
AMPK involves AMP binding to regulatory sites on the γ
subunits. This causes conformational changes that allos-
terically activate the enzyme and inhibit dephosphoryla-
tion of Thr172 within the activation loop of the catalytic
α subunit [12,13]. LKB1 has been identified as an
upstream kinase and shown to phosphorylate the α subu-
nit of AMPK at Thr172 [14-16]. However, metformin
most likely does not directly activate either LKB1 or AMPK
and the drug does not influence the phosphorylation of
AMPK by LKB1 in vitro [14,17,18]. Rather, there is evi-
dence that AMPK activation in response to metformin
treatment is downstream of effects on complex 1 of the
mitochondrial electron transport chain [19-22].
It is interesting to note that LKB1 is a well recognized
tumor suppressor and mutations in the gene encoding
LKB1 cause the rare inherited Peutz-Jeghers syndrome
[23]. It is believed that the LKB1-AMPK pathway functions
as a cellular energy-sensing checkpoint that controls cell
growth and proliferation according to the availability of
fuel supplies [24]. Considering the important role of the
LKB1-AMPK pathway in cell growth control, it is a poten-
tial target for cancer treatment or prevention. Metformin
stimulates this pathway and modulates tumor cell growth,
in vitro and in vivo, but its mode of action remains unclear.
In this report we demonstrate that metformin-sensitive
breast cancer cells arrest in G0/G1 due to activation of
AMPK, downregulation of cyclin D1, and enhanced bind-
ing of CDK2 by p27Kip1 and p21Cip1. AMPK is activated
and cyclin D1 is downregulated in a metformin-resistant
breast cancer cell line. However, this cell line becomes
sensitive to metformin when p27Kip1 or p21Cip1 is overex-
pressed. Thus, CDK inhibitors are essential for cell cycle
arrest in response to metformin. This is of significance
because p27Kip1 is often downregulated in cancer cells.
Results
Metformin treatment has cell line-dependent effects on 
breast cancer cells
While exploring the potential role of AMPK in regulating
p27Kip1 expression, we noted that metformin, an AMPK
activator, inhibits proliferation of MCF7 cells in a dose
dependent manner (Fig. 1A). We further explored the
effects of metformin on proliferation by treating a panel
of breast cancer cell lines with the drug at a concentration
of 8 mM. As shown by the work of Owen et al[21], this
represents a physiologically relevant dose of metformin.
Five of six breast cancer cell lines, including MCF7, BT20,
T47D, MDA-MB-453, and MDA-MB-474, underwent
growth arrest after metformin treatment (Fig. 1B). How-
ever, the cell line MDA-MB-231 was resistant to the effects
of metformin, showing only a slight decrease in prolifera-
tion over a four day period (Fig. 1B). These data indicate
that metformin has differential effects on cell prolifera-
tion in a breast cancer cell line-dependent manner. Fur-
thermore, there is no correlation between sensitivity to
metformin and the known status of estrogen receptor
(ER) expression, p53 mutation, or amplification of Her-
2[25,26].
Effects of metformin on cell cycle regulatory proteins in 
MCF7 cells
Since MCF7 cells were sensitive to metformin-mediated
inhibition of cell proliferation, we chose this cell line for
further experiments to characterize the molecular mecha-
nisms by which metformin arrests the cell cycle. In order
to determine the effects of metformin on cell cycle pro-
gression, MCF7 cells were treated with the drug for 1.5
days and then flow cytometry was performed on propid-
ium iodide stained cells (Fig. 2A). Metformin treatment
increased cells in G0/G1 phase from 61.4% to 71.7% and
decreased the number of cells in S phase from 32.2.54%
to 20.6%. These data suggest that metformin inhibits cell
cycle progression from G0/G1 into S phase. Therefore,
western blotting was used to examine the effects of met-
formin on various cell cycle regulatory proteins, including
cyclin E, cyclin D1, cyclin D2, cyclin A, CDK2, CDK4 and
the CDK inhibitors p27Kip1 and p21Cip1 (Fig. 2B). The
most remarkable change was the loss of cyclin D1 protein
after metformin treatment. The effects of metformin on
mRNA levels for several cell cycle regulatory proteins were
also examined. MCF7 cells were treated with or without
metformin for 1.5 days and then a multi-probe ribonucle-
ase protection assay (RPA) was performed. Cyclin D1
mRNA levels were notably lower in metformin treated
cells (Fig. 2C). When normalized to the house-keeping
gene L32, there was a 36.1% reduction of cyclin D1 mRNA
after metformin treatment. These data indicate that met-
formin-mediated downregulation of cyclin D1 is prima-
rily due to decreased levels of cyclin D1 mRNA.
One function of the cyclin D1/CDK complex is the bind-
ing and sequestration of p27Kip1 and p21Cip1. This pre-
vents these proteins from binding to and inhibiting the
cyclin E/CDK2 complex which promotes progression
from G0/G1 to S phase of the cell cycle[27] Since met-
formin causes downregulation of cyclin D1, this may leadJournal of Molecular Signaling 2008, 3:18 http://www.jmolecularsignaling.com/content/3/1/18
Page 3 of 11
(page number not for citation purposes)
Metformin inhibits proliferation of cultured breast cancer cells Figure 1
Metformin inhibits proliferation of cultured breast cancer cells. A. MCF7 cells were treated with metformin at the 
indicated concentrations for one day and then cell number was determined using a hemocytometer. The mean cell number 
from 3 independent cultures is shown. Error bars represent standard deviation. Using a t test, all treatments were significantly 
different from the control with P values of less than 0.01. B. Six different breast cancer cell lines were treated with 8 mM met-
formin. At the indicated times viable cell number was determined using a hemocytometer. The reported status of estrogen 
receptor (ER) expression, HER2 amplification, and p53 expression (Wild-type, WT, or mutant, mt) are indicated for each cell 
line. HER2+ indicates HER2 amplification while HER2- indicates normal HER2 expression. The data points represent the mean 
cell number from 3 independent cultures and error bars represent standard deviation.Journal of Molecular Signaling 2008, 3:18 http://www.jmolecularsignaling.com/content/3/1/18
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Effect of metformin on cell cycle progression and cell cycle regulatory proteins in MCF7 cells Figure 2
Effect of metformin on cell cycle progression and cell cycle regulatory proteins in MCF7 cells. A. Untreated cells 
(Con) or cells treated with 8 mM metformin for 1.5 days (Met) were stained with propidium iodide and then analyzed by flow 
cytometry to estimate the number of cells in each phase of the cell cycle. The experiment was repeated 3 times and the mean 
and standard error for each cell phase is indicated in the table. B. Equal amounts of protein from untreated cells (Con) or cells 
treated with metformin for 1.5 days (Met) were analyzed by western blotting using antibodies that recognize the indicated cell 
cycle regulatory proteins. β-Actin was detected as a loading control C. Total RNA was isolated from untreated cells (C) or 
cells treated with metformin (8 mM) for 1.5 days (M) and RNase protection assays were performed to detect the mRNAs 
encoding the indicated cyclins (left panel). Cyclin D1 mRNA levels were normalized using L32 mRNA levels (right panel). The 
mean of 3 independent experiments is shown and error bars indicate standard deviation. In a t test the value for the metformin 
treated cells was significantly different from the control with a P value of 0.006. D. MCF7 cells were treated with (Met) or 
without (Con) metformin (8 mM) and then extracts were prepared for immunoprecipitation (IP) using either a control anti-
body (C) or an anti-CDK2 antibody (CDK2). The immunoprecipitated proteins were analyzed by western blotting using anti-
bodies that recognize CDK2, p27Kip1 or p21Cip1 as indicated on the right.Journal of Molecular Signaling 2008, 3:18 http://www.jmolecularsignaling.com/content/3/1/18
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to release of p27Kip1 and p21Cip1, allowing them to bind to
CDK2 and block its activity. To test this, co-immunopre-
cipitation was used to monitor the levels of p27Kip1 and
p21Cip1 associated with CDK2 in cells treated with or with-
out metformin. Immunoprecipitation was performed
using anti-CDK2 antibody as well as an unrelated control
antibody of the same isotype. Then western blotting was
used to detect co-immunoprecipitated p27Kip1  and
p21Cip1 (Fig. 2D). CDK2 levels were similar in anti-CDK2
immunoprecipitates from metformin treated and
untreated cells. However the levels of p27Kip1 and p21Cip1
that co-immunoprecipitated with CDK2 were considera-
bly elevated in metformin treated cells. These results sup-
port the conclusion that metformin blocks MCF7 cells
from proliferating by decreasing cyclin D1 protein levels
leading to release of sequestered p27Kip1 and p21Cip1. The
released CDK inhibitors subsequently bind to and inhibit
cyclin E/CDK2 complex activity, leading to arrest in G0/
G1.
Downregulation of cyclin D1 involves activation of AMPK
Metformin may affect a variety of cellular pathways but
some of its effects are known to be due to enhanced activ-
ity of AMPK. It was therefore of interest to determine if
AMPK is activated in metformin treated cells and if this is
required for downregulation of cyclin D1. MCF7 cells
were treated with metformin for 1.5 days and then west-
ern blotting was used to examine the levels of the active
phosphorylated form of AMPK (phospho-Thr172). The
results show that metformin enhances phospho-AMPK
levels and that this correlates with downregulation of cyc-
lin D1 (Fig. 3A). Other reagents that are known to activate
AMPK, including antimycin A (1 μM) and AICAR (4 mM),
were also tested. Both reagents also led to increased AMPK
phosphorylation and decreased cyclin D1 protein levels
(Fig. 3B). To further examine this, MCF7 cells were pre-
treated with the AMPK-specific inhibitor compound C (20
μM) or DMSO (vehicle) for 1 day and then treated with or
without metformin for an additional 1.5 days. Cells were
harvested and western blotting was used to examine cyclin
D1 and phosphorylated ACC, a substrate of AMPK. Pre-
treatment with compound C blocks the reduction of cyc-
lin D1 caused by metformin treatment (Fig. 3C). This
corresponds to loss of ACC phosphorylation. These
results indicate that downregulation of cyclin D1 by met-
formin is through an AMPK-dependent pathway.
Stable overexpression of p27Kip1 in MDA-MB-231 cells 
leads to metformin sensitivity
MDA-MB-231 is an aggressive breast cancer cell line that
does not express estrogen receptors and has a mutated
form of p53 [25]. Our data show that metformin treat-
ment does not prevent cell proliferation in this cell line
(see Fig. 1). The lack of response to metformin treatment
in MDA-MB-231 cells provided us an opportunity to test
whether inhibition of cell proliferation by metformin is
dependent on cyclin D1 downregulation followed by
enhanced binding of the cyclin E/CDK2 complex by
p27Kip1 and p21Cip1. As indicated by an increased level of
the phosphorylated enzyme, metformin treatment
increased phospho-AMPK in MDA-MB-231 cells, similar
to that observed in MCF7 cells (Fig. 4A). This indicates
that MDA-MB-231 is responding to the drug. Also, cyclin
D1 was decreased in MDA-MB-231 cells (Fig. 4A). MDA-
MB-231 cells express p27Kip1  and p21Cip1  proteins at
greatly reduced levels compared to MCF7 cells (Fig. 4B).
This suggested the possibility that the resistance of MDA-
MB-231 cells is due to low levels of these CDK inhibitors.
Thus, even though cyclin D1 is downregulated in response
to metformin treatment, there are insufficient levels of
sequestered p27Kip1 and p21Cip1 to inhibit the activity of
cyclin E/CDK2. This is supported by the finding that phos-
phorylation of Rb at serine 795, a site targeted by
CDK2[28], is decreased in MCF7 cells but not in MDA-
MB-231 cells following metformin treatment (Fig. 4A). In
order to further test this hypothesis, we created a stable
cell line, MDA-MB-231-WTp27, which overexpresses wild
type p27Kip1 (Fig. 4C). Compared to MDA-MB-231 cells,
this stable cell line has a much higher level of p27Kip1.
Metformin treatment of MDA-MB-231-WTp27 cells
strongly inhibited proliferation (Fig. 4D). We have been
unsuccessful in establishing MDA-MB-231 cells that sta-
bly overexpress p21Cip1. However, transient transfection
of this line with an expression construct encoding p21Cip1
also caused them to become more sensitive to growth
inhibition in response to metformin (Fig. 4E). There was
no difference in cell death between the metformin treated
and untreated cultures as indicated by floating cells or
trypan blue staining (data not shown). These results sup-
port the conclusion that downregulation of cyclin D1,
alone, is not sufficient to arrest cells in response to met-
formin. CDK inhibitors p27Kip1  or p21Cip1  must be
expressed at sufficient levels such that their release and
subsequent inhibition of cyclin E/CDK2 leads to cell cycle
arrest.
Discussion
Several recent publications indicate that metformin has
inhibitory effects on tumor cell growth in vitro and in vivo
[1-9] The mechanisms through which metformin affects
cell cycle progression and tumor growth have not been
fully defined. The novel findings presented here are 1)
that metformin inhibits the proliferation of most cultured
breast cancer cell lines and that this does not correlate
with the status of ER, Her-2, or p53 expression; 2) cyclin
D1 levels are sharply downregulated in response to met-
formin but this alone is not sufficient to cause cell cycle
arrest; and 3) cell cycle arrest also requires sufficient levels
of CDK inhibitors (i.e. p27Kip1 or p21Cip1) to bind and
inhibit CDK2.Journal of Molecular Signaling 2008, 3:18 http://www.jmolecularsignaling.com/content/3/1/18
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Downregulation of cyclin D1 corresponds to activation of AMP-activated protein kinase Figure 3
Downregulation of cyclin D1 corresponds to activation of AMP-activated protein kinase. A. MCF7 cells were 
treated with (Met) or without (Con) metformin for 1.5 days and then western blotting was performed to detect active phos-
pho-AMPK, cyclin D1, and β-actin. B. MCF7 cells were treated with antimycin A (AM, 1 μM), AICAR (4 mM), or metformin (8 
mM) for 1.5 days. Control cells (Con) were treated with the appropriate vehicle for each reagent. Western blotting was per-
formed to detect active phospho-AMPK, cyclin D1, and β-actin. C. MCF7 cells were pretreated with DMSO (vehicle) or the 
AMPK-specific inhibitor compound C (20 μM) for 1 day and then treated with (Met) or without (Con) metformin for 1.5 days. 
Western blotting was performed to detect cyclin D1 or the phosphorylated form of the AMPK substrate ACC. β-actin was 
used as a loading control.Journal of Molecular Signaling 2008, 3:18 http://www.jmolecularsignaling.com/content/3/1/18
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Overexpression of p27Kip1 in the metformin-resistant MDA-MB-231 cell line leads to metformin sensitivity Figure 4
Overexpression of p27Kip1 in the metformin-resistant MDA-MB-231 cell line leads to metformin sensitivity. A. 
(Left panel) MCF7 and MDA-MB-231 cells were treated with (Met) and without (Con) metformin (8 mM) for 2 days. Western 
blotting was used to detect phospho-AMPK, total AMPK, p27Kip1, and β-actin. (Right panel) Same as A except that cell extracts 
were used to detect phospho-Rb (Serine 795), cyclin D1 or β-actin. B. Extracts from untreated MCF7 and MDA-MB-231 cells 
were used for western blotting of p27Kip1, p21Cip1, and β-actin. C. MDA-MB-231 cells were stably transfected with a construct 
encoding p27Kip1 that was tagged with a protein C epitope to derive the cell line MDA-MB-231WTp27. Extracts from the 
parental cell line (231) and the stably transfected cell line (231WTp27) were used for western blotting to detect the epitope-
tagged p27Kip1 (anti-Protein C epitope), p27Kip1 (p27), and β-actin. D. MDA-MB-231 cells or MDA-MB-231WTp27 cells were 
treated with (dashed lines) or without (solid lines) metformin (8 mM) for up to 3 days. At the indicated time points cell number 
was determined using a hemocytometer. Each data point represents the mean cell number from 3 independent cultures and 
error bars represent standard deviation. E. MDA-MB-231 cells were transiently transfected with a construct encoding p21Cip1 
or empty vector. They were then treated with metformin for the indicated time and cell number was determined as describe 
in D.Journal of Molecular Signaling 2008, 3:18 http://www.jmolecularsignaling.com/content/3/1/18
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Downregulation of cyclin D1 in response to metformin
has been demonstrated in LNCaP prostate cancer cells [8]
but the importance of CDK inhibitors was not addressed
in this study. These investigators did observe an small
increase in p27Kip1 levels following metformin treatment
of LNCaP cells. We have not observed significant changes
in the levels of CDK inhibitors in breast cancer cells.
Downregulation of cyclin D1 protein in response to met-
formin correlated with decreased cyclin D1 mRNA levels.
This suggests that metformin could initiate signaling path-
ways that lead to repression of the cyclin D1 gene. How-
ever, we have been unable to show any effect of
metformin on the human cyclin D1 promoter (-1063) in
luciferase reporter assays (data not shown). It is possible
that metformin targets elements outside of the 5'-flanking
region we have used for our experiments or that it causes
destabilization of the cyclin D1 mRNA.
In the studies performed by Sahra et al[8] using LNCaP
prostate cancer cells, inhibition of AMPK expression using
siRNAs did not prevent metformin-induced downregula-
tion of cyclin D1 or G0/G1 phase arrest. This is in contrast
with our results showing that compound C, a specific
inhibitor of AMPK, blocks metformin-induced downregu-
lation of cyclin D1 in MCF7 cells. Zakikhani et al[9] have
also shown that siRNAs targeting AMPK prevent growth
inhibition of MCF7 cells in response to metformin treat-
ment. The reasons for the differences are not known but
could be related to the different cell types and their spe-
cific genetic backgrounds.
The cell line MDA-MB-231 is resistant to the growth
inhibitory effects of metformin. It was previously reported
that this cell line does not express the AMPK kinase
LKB1[29,30]. It was also shown that MDA-MB-231 cells
do not respond to metformin in terms of inhibition of
protein translation through the mTOR pathway[29]. Our
data show that the active phosphorylated form of AMPK
increases in MDA-MB-231 cells in response to metformin.
We also show that cyclin D1 is downregulated in met-
formin treated MDA-MB-231. Thus MDA-MB-231 cells
are capable of responding to metformin and this could be
through AMPK kinases other than LKB1. Both calmodu-
lin-dependent protein kinase kinase [31-33] and ATM
have been shown to phosphorylate and activate
AMPK[34,35]. Further examination of these pathways will
be needed to determine if they play a role in AMPK activa-
tion in response to metformin.
Even though MDA-MB-231 cells respond to metformin in
terms of AMPK phosphorylation and cyclin D1 downreg-
ulation, these responses are not sufficient for cell cycle
arrest. This cell line expresses very low levels of p27Kip1
and p21Cip1. When p27Kip1 is overexpressed, these cells
stop proliferating following metformin treatment. We
also found that overexpression of p21Cip1 sensitized the
cells to cell cycle arrest in response to metformin, indicat-
ing that either CDK2 inhibitor is capable of mediating this
effect. Thus, CDK inhibitors are important mediators of
the observed cell cycle arrest and appear to act down-
stream of AMPK activation and cyclin D1 loss. Other
AMPK activators such as AICAR and antimycin A also
caused downregulation of cyclin D1. A previous report
showed that the proliferation of metformin-resistant
MDA-MB-231 cells is inhibited by AICAR[36]. Thus, even
though both reagents stimulate AMPK activity, the cellular
responses to metformin and AICAR are not the same in
MDA-MB-231 cells. AICAR is thought to activate AMPK by
mimicking AMP, but it has been shown to have AMPK-
independent effects on cells[37,38]. For metformin, it is
thought that the primary target is complex I of the mito-
chondrial respiratory chain and that this is upstream of
AMPK activation [19-22].
Using mouse embryo fibroblasts, Jones et al[39] showed
that activation of AMPK induces phosphorylation of p53
and that this is required for AMPK-dependent cell cycle
arrest. The same group showed, using paired isogenic
colon cancer cell lines, that metformin selectively inhib-
ited p53 negative tumor cell growth in vivo[3] With the
panel of cultured breast cancer cell lines used in our exper-
iments, we have not observed any correlation between
either cell cycle arrest or cell survival and p53 expression.
For example, of the cell lines shown in Fig. 1, all but MCF7
have been reported to carry p53 mutations[26], yet only
MDA-MB-231 is resistant to the growth inhibitory effects
of metformin in culture.
Conclusion
Our data provide a molecular mechanism that may con-
tribute to the ability of metformin to have beneficial
effects on preventing or treating cancer. Our model (Fig.
5) is that metformin arrests cell proliferation by activating
AMPK. Active AMPK leads to loss of cyclin D1 mRNA and
protein. The decline in cyclin D1 levels causes the release
of sequestered CDK inhibitors, p27Kip1 and p21Cip1, which
then bind to and inhibit the cyclin E/CDK2 complex. This
prevents progression from G1 into S phase and blocks cell
proliferation. Resistance to metformin mediated cell cycle
arrest is observed when cells express low levels of p27Kip1
or p21Cip1. Loss of p27Kip1  expression is commonly
observed in many types of cancer and is often correlated
with poor prognosis. Therefore our findings may be of sig-
nificance for development and use of anti-tumor drugs,
such a metformin, that target the AMPK signaling path-
way.
Methods
Chemicals
The following chemicals were used in this study: met-
formin (1, 1-dimethylbiguanide, Sigma Chemical Co),
AICAR (5-aminoimidazole-4-carboxamide-riboside,Journal of Molecular Signaling 2008, 3:18 http://www.jmolecularsignaling.com/content/3/1/18
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Sigma Chemical Co.), AMPK inhibitor (Compound C,
Calbiochem), antimycin A (Sigma Chemical Co.).
Cell culture
All human breast cancer cell lines were purchased from
ATCC and maintained in Dulbecco's modified Eagle's
medium (DMEM) with 10% fetal bovine serum supple-
mented with 100 U/ml penicillin and 100 μg/ml strepto-
mycin in a humidified CO2 incubator.
Cell proliferation assay
Human breast cancer cells were plated into 35 mm dishes.
After one day cells were treated with metformin at the
indicated concentrations or the same volume of sterilized
water. After incubation with metformin for 1, 2 or 3 days,
cells were extensively rinsed in Dulbecco's phosphate
buffered saline (PBS) to remove any loosely attached or
floating cells. The cells were then harvested by trypsiniza-
tion and cell number was determined using a hemocy-
tometer.
Western blotting
Cells in 35 mm dishes were rinsed with PBS and lysed by
addition of sodium dodecylsulfate (SDS) sample buffer
[2.5 mM Tris-HCl (pH 6.8), 2.5% SDS, 100 mM dithioth-
reitol, 10% glycerol, 0.025% pyronine Y]. Equal protein
amounts were separated on 10% SDS-polyacrylamide
gels. Proteins were transferred to Immobilon P mem-
branes (Millipore) using a Bio-Rad Trans-blot apparatus
with a transfer buffer of 48 mM Tris-HCl and 39 mM gly-
cine. The membranes were blocked with 5% non-fat dry
milk in Tris-buffered saline [10 mM Tris-HCl (pH 7.5),
150 mM NaCl] containing 0.1% Tween-20 (TBS-T) for
15–60 minutes at room temperature. The membrane was
then incubated with the appropriate antibody in TBS-T
containing 5% non-fat dry milk for 1 hour at room tem-
perature or overnight at 4°C. After extensive washing in
TBS-T the membrane was incubated with the appropriate
horseradish peroxidase (HRP)-conjugated secondary anti-
body. After extensive washing in TBS-T, proteins were
detected using the Super Signal West Pico chemilumines-
cent substrate (Pierce Biochemical). Anti-β-actin mono-
clonal antibody (A5441, used at 1:10,000) was purchased
from Sigma. Antibodies against cyclin D1 (sc-753, used at
1:2500), cyclin D2 (sc-452, used at 1:2500), cyclin A (sc-
751, used at 1:2500), cyclin E (sc-481, used at 1:2500),
CDK2 (sc-163, used at 1:2500), CDK4 (sc-260, used at
1:2500), and p21Cip1 (sc-817, used at 1:1000) were pur-
chased from Santa Cruz Biotechnology. p27Kip1(610241,
used at 1:2500) antibody was purchased from BD Bio-
sciences. Antibodies against phosphorylated AMPK phos-
phorylated at threonine 172 (2535, used at 1:1000),
AMPK (2532, used at 1:1000), and phospho-ACC (3661,
used at 1:1000) were purchased from Cell Signaling Tech-
nology. Anti-protein C (1814508, used at 1:500) was pur-
chased from Roche Applied Science. Secondary
horseradish peroxidase-linked anti-mouse (31430, used
at 1:5000) and anti-rabbit (31460, used at 1:5000) IgG
antibodies were purchased from Pierce Biochemical.
Immunoprecipitation
Cell extracts were prepared using a lysis buffer consisting
of 50 mM HEPES, (pH 7.5), 150 mM NaCl, 1 mM EDTA,
2.5 mM EGTA, 10% glycerol, 0.1% Tween-20, 1 mM DTT,
1 mM NaF, 0.1 mM Na3VO4, 10 μg/ml leupeptin, 2 μg/ml
Aprotinin, and 0.1 mM PMSF. Extracts were briefly soni-
cated and then centrifuged at 14,000 rpm in a
MicroCL17R refrigerated microcentrifuge at 4°C for 15
min. Protein concentration was determined using the Bio-
Rad protein assay. Equal amounts of total protein from
each extract (0.5 to 1 mg) were used for analysis. Cell
lysates were incubated with 2 μg of CDK2 antibody over-
night at 4°C on a rotator. Protein A-conjugated agarose
beads (30 μl) were added, and the incubation continued
for 1 hour on a rotator. The beads were pelleted at 4,000
rpm using MicroCL17R refrigerated microcentrifuge at
4°C, the supernatant was discarded and the beads were
washed five times in 500 μl lysis buffer. The precipitated
proteins were dissolved in SDS-sample buffer, separated
by SDS-PAGE and then p27Kip1, p21Cip1 and CDK2 were
detected by western blotting.
Ribonuclease protection assay (RPA)
RPAs were carried out with the RiboQuant Multi-Probe
RNase Protection Assay System (BD Biosciences). Human
probe set hCYC-1 includes templates for cyclin A, cyclin B,
cyclin C, cyclin D1, cyclin D2, cyclin D3, and cyclin A1, as
well as for ribosomal protein L32 and GAPDH as controls.
Probes were synthesized at room temperature using 32P-
UTP and T7 RNA polymerase. Total cellular RNA was iso-
lated using TRI Reagent (Molecular Research Center). The
labeled riboprobe set was hybridized to 15 μg of RNA at
56°C for 12–16 h. After hybridization, free riboprobes
and single-stranded RNA were digested with an RNase A
and RNase T1 mixture at 30°C for 45 min. This was fol-
lowed by treatment with proteinase K at 37°C. The
remaining protected RNA fragments were purified by phe-
nol-chloroform-isoamyl alcohol extraction followed by
ethanol precipitation. The pellet was dried, dissolved in 5
μl loading buffer, heated at 90°C for 3 minutes and then
placed in an ice bath. The sample was separated using a
4.75% denaturing polyacrylamide gel. The undigested
labeled probe set was used as a marker. After electrophore-
sis RNase-protected bands were visualized by autoradiog-
raphy using Kodak Biomax XAR film. The quantity of each
mRNA species was estimated using a ChemiImager sys-
tem.
Transfection and selection of stable cell lines
MDA-MB-231 cells in 35 mm dishes were transfected with
the construct pcDNA3.1-p27-protein C using Lipo-
fectamine reagent (Invitrogen). After one day the cellsJournal of Molecular Signaling 2008, 3:18 http://www.jmolecularsignaling.com/content/3/1/18
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were plated into 100 mm dishes and then selection with
hygromycin (200 μg/ml) was initiated two days later.
New medium with hygromycin was added every three
days. After three weeks of selection, colonies were picked,
expanded, and then tested by western blotting using anti-
protein C and anti-p27 antibodies.
Flow cytometry
MCF7 cells were treated with or without metformin for
1.5 days. Cells (1 × 106) were trypsinized and fixed in 70%
ethanol overnight. Fixed cells were stained with propid-
ium iodide (50 μg/ml) for 30 minutes at room tempera-
ture. Cells were filtered using a 5 ml polystyrene round-
bottom tube with a cell-strainer cap (BD Falcon) prior to
flow cytometry. All flow cytometry measurements were
done using a FACSVantage SE cell sorter (Becton Dickin-
son). Cell cycle analysis was performed using ModFit LT
software.
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